Shingles Vaccine Linked to Lower Heart Disease Risk
- SEOUL, South Korea (AP) — A new study published in the European Heart journal suggests that the shingles vaccine may offer protection against cardiovascular events, including stroke,...
- The study, led by Professor Dong Keon Yon of the College of Medicine at the University of Kyung Hee, analyzed data from 1,271,922 individuals aged 50 and older...
- The study primarily examined the effects of a live attenuated shingles vaccine.
Shingles vaccine Associated With Reduced Heart Disease Risk, Study Finds
Table of Contents
- Shingles vaccine Associated With Reduced Heart Disease Risk, Study Finds
- Shingles Vaccine and Heart health: your Questions Answered
- What does the new study on the shingles vaccine say about heart disease risk?
- How was this study conducted?
- What are the key findings of the study?
- How long does the protection from the shingles vaccine last?
- Why might the shingles vaccine reduce heart disease risk?
- Did the study examine different types of shingles vaccines?
- What are the limitations of this study?
- Can you summarize the key benefits of getting the shingles vaccine?
- Where can I find more data about the shingles vaccine?
SEOUL, South Korea (AP) — A new study published in the European Heart journal suggests that the shingles vaccine may offer protection against cardiovascular events, including stroke, heart failure, and coronary heart disease. The research, involving over 1.2 million participants, indicates that the vaccine’s protective effects can last for up to eight years.
Study Details and Findings
The study, led by Professor Dong Keon Yon of the College of Medicine at the University of Kyung Hee, analyzed data from 1,271,922 individuals aged 50 and older in South korea. Researchers tracked participants from 2012, collecting data on shingles vaccination status and cardiovascular health, while also considering factors like age, sex, socioeconomic status, and lifestyle.
The study primarily examined the effects of a live attenuated shingles vaccine. According to the researchers, this type of vaccine is being replaced in many countries by a recombinant vaccine containing a protein from the varicella-zoster virus.
Results showed that vaccinated individuals had a 23% lower risk of cardiovascular events overall. Specifically, the risk of major cardiovascular events (stroke, heart attack, or death due to heart disease) was reduced by 26%, as was the risk of heart failure. The risk of other cardiac issues decreased by 22%.
Long-Term Protection
While the strongest protection was observed in the two to three years following vaccination, the study indicated that the protective benefits could extend for provided that eight years.
Expert Commentary
Professor Yon emphasized the potential broader health benefits of the shingles vaccine. “Our study suggests that the vaccine against shingles can contribute to lowering the risk of heart disease, even in people without known risk factors,” he said. “This means that vaccination may provide health benefits beyond preventing shingles.”
Yon explained that shingles infection can cause blood vessel damage, inflammation, and clot formation, perhaps leading to heart disease. By preventing shingles, the vaccine may mitigate these risks.
He also noted the study’s strengths, stating, “This is one of the largest and most extensive studies that follow a healthy general population over a period of up to 12 years. For the first time, this allowed us to examine the association between vaccination against shingles and 18 different types of cardiovascular disease.”
Limitations and Future Research
Yon cautioned that the findings, based on an Asian cohort, may not be generalizable to all populations. He also pointed out that the live attenuated vaccine is not suitable for everyone, necessitating further research on the recombinant vaccine. Additionally, the study establishes an association but not a direct causal relationship.
Professor Yon and his team plan to investigate the impact of the recombinant vaccine to determine if it offers similar cardiovascular benefits.
Shingles Vaccine and Heart health: your Questions Answered
What does the new study on the shingles vaccine say about heart disease risk?
A recent study published in the *European Heart Journal* suggests that the shingles vaccine may offer protection against cardiovascular events, including stroke, heart failure, and coronary heart disease. The research indicates that the vaccine’s protective effects can last for up to eight years.
How was this study conducted?
The study, led by Professor Dong Keon Yon, analyzed data from 1,271,922 individuals aged 50 and older in South Korea. Researchers tracked participants from 2012, collecting data on shingles vaccination status and cardiovascular health. The study also considered factors like age, sex, socioeconomic status, and lifestyle.
What are the key findings of the study?
Vaccinated individuals had a 23% lower risk of cardiovascular events overall. Specifically:
- The risk of major cardiovascular events (stroke, heart attack, or death due to heart disease) was reduced by 26%.
- The risk of heart failure was also reduced by 26%.
- The risk of other cardiac issues decreased by 22%.
How long does the protection from the shingles vaccine last?
While the strongest protection was observed in the two to three years following vaccination, the study indicates that the protective benefits could extend for up to eight years.
Why might the shingles vaccine reduce heart disease risk?
Professor Yon explained that shingles infection can cause blood vessel damage, inflammation, and clot formation.The shingles vaccine may help to prevent these issues, and thereby reduce the risk of heart disease.
Did the study examine different types of shingles vaccines?
The study primarily examined the effects of a live attenuated shingles vaccine. Tho, this type of vaccine is being replaced in many countries by a recombinant vaccine. Professor Yon and his team plan to investigate the impact of the recombinant vaccine to determine if it offers similar cardiovascular benefits.
What are the limitations of this study?
The findings,based on an Asian cohort,may not be generalizable to all populations. Also,the live attenuated vaccine is not suitable for everyone,and the study found an association between the vaccine and reduced heart disease risk,but does not establish a direct causal relationship.
Can you summarize the key benefits of getting the shingles vaccine?
This table summarizes the key benefits.
| Benefit | Description |
|---|---|
| Reduced Risk of Cardiovascular Events | Overall risk reduced by 23% |
| protection Against Major events | 26% lower risk of heart attack, stroke, or heart disease-related death. |
| Protection Against Heart Failure | 26% lower risk of Heart Failure. |
| Long-Term Protection | Benefits may last up to eight years. |
Where can I find more data about the shingles vaccine?
Consult with your healthcare provider.Also, the study was published in the *European Heart Journal*, a reputable medical journal.